Clopidogrel after PCI was noninferior to aspirin for net adverse clinical events but superior in reducing secondary endpoints of stroke and MI, in 5-year STOPDAPT-2 results.
The WHO has decided to not add GLP-1 receptor agonists indicated for weight loss to its 2023 essential medicines list. Data are lacking on long term efficacy, the WHO said.